SCHEMBL4741402

SCHEMBL4741402

COc1ccc2cc(CNCc3ccco3)c(-c3ccsc3)nc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 17/20 0.72
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
GLA P06280 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.45
PKM P14618 1/20 0.45
MAPK1 P28482 1/20 0.45
CASP1 P29466 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4879752 0.84 GPBAR1 (1.00) GPBAR1PDGFRBPDGFRA
SCHEMBL4880446 0.84 GPBAR1 (1.00) GPBAR1PDGFRBPDGFRA
SCHEMBL4880217 0.81 GPBAR1 (0.86) GPBAR1PDGFRBPDGFRA
SCHEMBL4874706 0.81 GPBAR1 (1.00) GPBAR1PDGFRBPDGFRA
SCHEMBL4881414 0.80 GPBAR1 (0.71) GPBAR1NPC1PDGFRBPDGFRA
SCHEMBL4873616 0.80 GPBAR1 (0.80) GPBAR1KDM4EALDH1A1GLAPOLB
SCHEMBL4871712 0.79 GPBAR1 (0.76) GPBAR1MAPTPDGFRBPDGFRA
SCHEMBL4739253 0.79 GPBAR1 (0.82) GPBAR1PDGFRBPDGFRA
SCHEMBL4786119 0.79 GPBAR1 (0.77) GPBAR1KDM4EALDH1A1HPGDPOLB
SCHEMBL4740522 0.78 GPBAR1 (0.83) GPBAR1PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-09-11 US disclosed
WO-2008097976-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221161-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE GPR119, GPBAR1, LDLR GPBAR1 2/4885KDM4E 3744/4885ALDH1A1 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.